CCDC90A Activators
The class of CCDC90A activators encompasses a variety of compounds that influence specific cellular pathways, thereby enhancing the functional activity of CCDC90A. Forskolin, for instance, acts by raising intracellular cAMP levels, a second messenger that can activate protein kinase A (PKA) and modulate various signaling pathways. An increase in cAMP may indirectly activate CCDC90A by bolstering thesignal transduction cascades in which it participates. Similarly, 8-Bromo-cAMP, a synthetic analog of cAMP, and Rolipram, a phosphodiesterase inhibitor, also elevate cAMP levels, potentially enhancing CCDC90A activity through similar mechanisms. PIP3 and EGF specifically cater to membrane-associated signaling. PIP3 directly recruits proteins with pleckstrin homology domains to the cell membrane, which could include CCDC90A, thereby potentiating its activity. EGF, through its receptor activation, initiates a cascade potentially involving CCDC90A, thereby enhancing its function as part of the downstream signaling events.
Calcium signaling is another crucial modulator for CCDC90A activators; Ionomycin, Thapsigargin, and A23187 (Calcimycin) each raise intracellular calcium levels, albeit through different mechanisms, such as acting as a calcium ionophore or inhibiting calcium ATPases. The resultant upsurge in calcium may activate CCDC90A if it is implicated in calcium-dependent pathways. Phorbol 12-myristate 13-acetate (PMA) activates protein kinase C (PKC), possibly increasing CCDC90A activity if it is regulated by PKC-mediated phosphorylation events. U0126 and PD98059 are both MEK inhibitors, and their action might lead to the enhancement of CCDC90A activity through the initiation of compensatory signaling routes. LY294002, a PI3K inhibitor, similarly may activate alternative pathways that could culminate in the upregulation of CCDC90A activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, leading to an increase in cAMP levels. Elevated cAMP may enhance CCDC90A activation by promoting a favorable environment for its signaling cascade, as cAMP is a secondary messenger in various signaling pathways that CCDC90A may be involved in. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin acts as an ionophore for calcium, raising intracellular calcium levels. An increase in calcium concentration can activate calcium-dependent signaling pathways, potentially enhancing the functional activity of CCDC90A if it is calcium-sensitive or involved in calcium-dependent processes. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that can activate PKA and other cAMP-dependent processes. This may enhance CCDC90A activity if it is regulated by cAMP-responsive elements or associated pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to an increase in cytosolic calcium levels. This can enhance CCDC90A activity by activating calcium-dependent signaling pathways if CCDC90A is a part of or regulated by such pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram inhibits phosphodiesterase 4 (PDE4), leading to an increase in cAMP levels by preventing its breakdown. Elevated cAMP levels can enhance CCDC90A activity if it is part of or regulated by cAMP-dependent pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is an ionophore that selectively transports calcium across cell membranes. By increasing intracellular calcium, it can enhance CCDC90A activity if CCDC90A is sensitive to calcium signaling or involved in calcium-dependent pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which is involved in controlling the function of other proteins through the phosphorylation of hydroxyl groups of serine and threonine amino acid residues. If CCDC90A is a substrate for PKC or is regulated by PKC-dependent pathways, its activity could be enhanced. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which can lead to the activation of alternative compensatory pathways that could enhance the activity of CCDC90A if it is involved in such pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which similarly to U0126, can cause the activation of alternative pathways that may enhance CCDC90A activity if it is linked to these alternative signaling routes. | ||||||